Literature DB >> 29229122

Use of imaging during symptomatic follow-up after resection of pancreatic ductal adenocarcinoma.

Vincent P Groot1, Lois A Daamen1, Jeroen Hagendoorn1, Inne H M Borel Rinkes1, Hjalmar C van Santvoort2, I Quintus Molenaar3.   

Abstract

BACKGROUND: Controversy exists whether follow-up after resection of pancreatic ductal adenocarcinoma (PDAC) should include standardized imaging for the detection of disease recurrence. The purpose of this study was to evaluate how often patients undergo imaging in a setting where routine imaging is not performed. Secondly, the pattern, timing, and treatment of recurrent PDAC were assessed.
MATERIALS AND METHODS: This was a post hoc analysis of a prospective database of all consecutive patients undergoing pancreatic resection of PDAC between January 2011 and January 2015. Data on imaging procedures during follow-up, recurrence location, and treatment for recurrence were extracted and analyzed. Associations between clinical characteristics and post-recurrence survival were assessed with the log-rank test and Cox univariable and multivariable proportional hazards models.
RESULTS: A total of 85 patients were included. Seventy-four patients (87%) underwent imaging procedures during follow-up at least once, with a mean amount of 3.1 ± 1.9 imaging procedures during the entire follow-up period. Sixty-eight patients (80%) were diagnosed with recurrence, 58 (85%) of whom after the manifestation of clinical symptoms. Additional tumor-specific treatment was administered in 17 of 68 patients (25%) with recurrence. Patients with isolated local recurrence, treatment after recurrence, and a recurrence-free survival >10 mo had longer post-recurrence survival.
CONCLUSIONS: Even though a symptomatic follow-up strategy does not include routine imaging, the majority of patients with resected PDAC underwent additional imaging procedures during their follow-up period. Further prospective studies are needed to determine the actual clinical value, psychosocial implications, and cost-effectiveness of different forms of follow-up after resection of PDAC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Follow-up studies; Pancreatectomy; Pancreatic neoplasms; Recurrence; Survival

Mesh:

Year:  2017        PMID: 29229122     DOI: 10.1016/j.jss.2017.08.023

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

2.  Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.

Authors:  Yong Liu; Tao Wang; Ziqi Fang; Junjie Kong; Jun Liu
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-21       Impact factor: 4.553

3.  Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Ding Ding; Ammar A Javed; Richard A Burkhart; Jun Yu; Inne H Borel Rinkes; I Quintus Molenaar; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg Oncol       Date:  2018-06-14       Impact factor: 5.344

4.  Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy.

Authors:  Andreas Minh Luu; Orlin Belyaev; Philipp Höhn; Michael Praktiknjo; Monika Janot; Waldemar Uhl; Chris Braumann
Journal:  J Gastrointest Oncol       Date:  2021-04

5.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2019-06       Impact factor: 13.787

Review 6.  Comparative efficacy of modified FOLFIRINOX, gemcitabine plus capecitabine and gemcitabine plus nab-paclitaxel as adjuvant treatment for resected pancreatic cancer: a Bayesian network meta-analysis.

Authors:  Victor Hugo Fonseca de Jesus; Rachel P Riechelmann
Journal:  Ecancermedicalscience       Date:  2021-08-16

Review 7.  Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.

Authors:  R Casolino; C Braconi; G Malleo; S Paiella; C Bassi; M Milella; S B Dreyer; F E M Froeling; D K Chang; A V Biankin; T Golan
Journal:  Ann Oncol       Date:  2020-11-26       Impact factor: 32.976

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.